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B vitamins in patients with recent transient ischaemic attack 
or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: 
a randomised, double-blind, parallel, placebo-controlled trial
The VITATOPS Trial Study Group*
Summary
Background Epidemiological studies suggest that raised plasma concentrations of total homocysteine might be a risk 
factor for major vascular events. Whether lowering total homocysteine with B vitamins prevents major vascular events 
in patients with previous stroke or transient ischaemic attack is unknown. We aimed to assess whether the addition 
of once-daily supplements of B vitamins to usual medical care would lower total homocysteine and reduce the 
combined incidence of non-fatal stroke, non-fatal myocardial infarction, and death attributable to vascular causes in 
patients with recent stroke or transient ischaemic attack of the brain or eye.
Methods In this randomised, double-blind, parallel, placebo-controlled trial, we assigned patients with recent stroke 
or transient ischaemic attack (within the past 7 months) from 123 medical centres in 20 countries to receive one tablet 
daily of placebo or B vitamins (2 mg folic acid, 25 mg vitamin B6, and 0·5 mg vitamin B12). Patients were randomly 
allocated by means of a central 24-h telephone service or an interactive website, and allocation was by use of random 
permuted blocks stratiﬁ ed by hospital. Participants, clinicians, carers, and investigators who assessed outcomes were 
masked to the assigned intervention. The primary endpoint was the composite of stroke, myocardial infarction, or 
vascular death. All patients randomly allocated to a group were included in the analysis of the primary endpoint. This 
trial is registered with ClinicalTrials.gov, NCT00097669, and Current Controlled Trials, ISRCTN74743444.
Findings Between Nov 19, 1998, and Dec 31, 2008, 8164 patients were randomly assigned to receive B vitamins (n=4089) 
or placebo (n=4075). Patients were followed up for a median duration of 3·4 years (IQR 2·0–5·5). 616 (15%) patients 
assigned to B vitamins and 678 (17%) assigned to placebo reached the primary endpoint (risk ratio [RR] 0·91, 95% CI 
0·82 to 1·00, p=0·05; absolute risk reduction 1·56%, –0·01 to 3·16). There were no unexpected serious adverse 
reactions and no signiﬁ cant diﬀ erences in common adverse eﬀ ects between the treatment groups.
Interpretation Daily administration of folic acid, vitamin B6, and vitamin B12 to patients with recent stroke or 
transient ischaemic attack was safe but did not seem to be more eﬀ ective than placebo in reducing the incidence of 
major vascular events. These results do not support the use of B vitamins to prevent recurrent stroke. The results of 
ongoing trials and an individual patient data meta-analysis will add statistical power and precision to present estimates 
of the eﬀ ect of B vitamins.
Funding Australia National Health and Medical Research Council, UK Medical Research Council, Singapore 
Biomedical Research Council, Singapore National Medical Research Council, Australia National Heart Foundation, 
Royal Perth Hospital Medical Research Foundation, and Health Department of Western Australia.
Introduction
After an ischaemic stroke or transient ischaemic attack of 
the brain or eye, patients remain at increased risk of 
future stroke, myocardial infarction, or vascular death 
(major vascular events) despite use of medical and 
surgical therapies.1 Cross-sectional and observational 
epidemiological studies suggest that raised plasma 
concentrations of total homocysteine are a common 
causal risk factor for major vascular events.2–4 Further-
more, randomised trials show that total homocysteine 
can be lowered by supplementary treatment with 
B vitamins: 0·5–5·0 mg folic acid daily lowers total 
homo cysteine by 25% (95% CI 23–28%) and 0·02–1·00 mg 
vitamin B12 (mean 0·50 mg) daily lowers total 
homocysteine by 7% (3–10%).5 However, whether 
lowering total homocysteine prevents major vascular 
events in patients with stroke and transient ischaemic 
attack is unknown. There have been no placebo-controlled 
trials of B vitamins in patients with stroke or transient 
ischaemic attack. The only previous randomised trial of 
treatment with B vitamins in patients with a history of 
stroke—the Vitamins Intervention for Stroke Prevention 
(VISP) trial6—compared high-dose B vitamins (25 mg 
pyridoxine, 0·4 mg cobalamin, and 2·5 mg folic acid) 
with low-dose B vitamins (200 μg pyridoxine, 6 μg 
cobalamin, and 20 μg folic acid) and was stopped because 
of futility after 3680 patients had been followed up for a 
mean of 20 months. There was no diﬀ erence in the 
primary outcome of cerebral infarction between the 
groups (risk ratio [RR] 1·0, 95% CI 0·8–1·3), despite a 
mean reduction of total homocysteine of 2 μmol/L among 
patients assigned to high-dose B vitamins compared with 
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those assigned to low-dose B vitamins.6 However, in an 
eﬃ  cacy analysis of 2155 patients who were deemed most 
likely to beneﬁ t from treatment with B vitamins 
(ie, excluding patients with low vitamin B12 concentrations 
who were unable to absorb oral vitamin B12 and patients 
with high vitamin B12 concentrations who were already 
taking a vitamin B12 supplement), there was a 21% 
(95% CI 0–37%) reduction in the combined outcome of 
ischaemic stroke, coronary disease, or death in patients 
assigned to high-dose B vitamins compared with those 
assigned to low-dose B vitamins.7
Trials in other populations of patients have not shown a 
signiﬁ cant beneﬁ t of B vitamins compared with placebo 
in reducing major vascular events.8–22 This absence of 
detectable beneﬁ t has several possible explanations: there 
might have been too few outcome events to provide 
suﬃ  cient statistical power for a modest but clinically 
important eﬀ ect to be reliably identiﬁ ed or excluded; the 
doses of B vitamins might have been too low; the duration 
of treatment with B vitamins might have been too short; 
results might have been aﬀ ected by food concurrently 
being fortiﬁ ed with folic acid; and, if total homocysteine 
is a marker and not a cause of vascular risk, lowering total 
homocysteine might have no eﬀ ect on vascular risk. 
The VITAmins TO Prevent Stroke (VITATOPS) trial 
aimed to test the hypothesis that the addition of once-
daily supplements of B vitamins to usual medical care 
would reduce the combined incidence of non-fatal stroke, 
non-fatal myocardial infarction, and death attributable to 
vascular causes among patients with recent stroke or 
transient ischaemic attack of the brain or eye.23,24
Methods
Patients
The rationale and design of the VITATOPS trial have 
been published previously.23,24 Brieﬂ y, VITATOPS was 
a prospective, randomised, double-blind, placebo-
controlled clinical trial involving 123 medical centres in 
20 countries from four continents. VITATOPS was 
undertaken in accordance with the Declaration of 
Helsinki and the CONSORT guidelines.25,26
Patients were eligible for inclusion if they had had a 
stroke (ischaemic or haemorrhagic) or transient ischaemic 
attack (eye or brain), as deﬁ ned by standard criteria,27 
within the past 7 months. Patients with haemorrhagic 
stroke were included because the underlying cause is 
frequently intracranial small vessel disease27 and the 
prognosis can include ischaemic strokes and coronary 
events that might respond to B-vitamin therapy.28,29 We 
chose the cutoﬀ  of 7 months to allow for the inclusion of 
patients who had already been enrolled in an acute stroke 
treatment trial and who needed to complete the ﬁ nal 
6-month follow-up for that trial before they could be 
eligible to enrol in other trials, such as VITATOPS. 
Patients were excluded if they were taking folic acid, 
vitamin B6, vitamin B12, or a folate antagonist 
(eg, methotrexate); if they were pregnant or were women 
of childbearing potential; or if they had a limited life 
expectancy (eg, because of ill health).
The trial received ethics approval from national (India, 
New Zealand, and the UK) and local research ethics 
committees and all patients provided written informed 
consent before enrolment.24
Randomisation and masking
Patients were randomly assigned to receive either 
B vitamins (2 mg folic acid, 25 mg vitamin B6, and 
0·5 mg vitamin B12) or matching placebo that had the 
same colour and coating. Random allocation was done by 
use of a central 24 h telephone service or an interactive 
website by use of random permuted blocks stratiﬁ ed by 
hospital. Patients, clinicians, trial coordinators, and 
outcome investigators were masked to treatment 
allocation. The data monitoring and safety committee, 
who were unmasked to treatment allocation, reviewed 
the safety data every 6 months and reported to the 
steering committee.
Procedures
Demographic and clinical characteristics of the participants 
were recorded at baseline. Investigators were encouraged, 
but not obligated, to take a fasting blood sample from 
For the trial protocol see http://
vitatops.highway1.com.au/html/
index.asp?section=pro
Figure 1: Trial proﬁ le
TIA=transient ischaemic attack.
8164 randomised
4089 assigned to B vitamins 4075 assigned to placebo
4089 analysed for primary outcome 4075 analysed for primary outcome
 158 did not take any trial tablets
 19 had qualifying event misdiagnosed (ie, not stroke or TIA)
 1 did not provide written informed consent
 1 was taking folate, vitamin B6, and vitamin B12 and was  
  unwilling to stop non-trial B vitamins for trial drugs
 348 lost to follow-up
 164 did not take any trial tablets
 8 had qualifying event misdiagnosed 
  (ie, not stroke or TIA)
 354 lost to follow-up
For the interactive website see 
http://vitatops.highway1.com.au
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consenting patients to measure blood concentrations of 
total homocysteine (fasting), red cell folate, vitamin B12, 
and creatinine. Patients were followed up every 6 months 
after random allocation until completion of the trial.
The primary outcome was the composite of non-fatal 
stroke, non-fatal myocardial infarction, or death from 
any vascular causes, whichever occurred ﬁ rst. Secondary 
outcomes were stroke (non-fatal or fatal); myocardial 
infarction (non-fatal or fatal); death from any vascular 
cause; death from any cause; revascularisation 
procedures; the composite of non-fatal stroke, non-fatal 
myocardial infarction, and death from any vascular cause; 
and revascularisation procedures of the coronary, 
cerebral, or peripheral circulation. All investigator-
reported outcomes and adverse events were audited by a 
masked adjudication committee.
Statistical analysis
Our sample size calculations were based on equally sized 
intervention and placebo groups, a minimum follow-up 
of 6 months for the last patient to be randomly allocated, 
an annual primary outcome event rate of 8% in the 
placebo group,30 and a 15% decrease in the relative risk of 
the primary outcome among patients assigned to 
B vitamins (ie, 6·8% per year) compared with placebo. 
For a type 1 error of 5% and type 2 error of 20%, and 
assuming a mean follow-up of 2 years, a sample size of 
3982 patients was required in each treatment group.
When recruitment began in November, 1998, we planned 
to complete the trial by the end of 2004.23 Patients were 
therefore asked to consent to 5 years of follow-up. In 2004, 
when the initial patients had completed 5 years of follow-
up, 4000 of the target of 7964 patients had been enrolled, 
and the primary outcome event rate in the trial population 
was 5·1% rather than 6·8–8%. While still masked to the 
event rates in each treatment group, the steering committee 
decided to increase the sample size and extend the duration 
of follow-up until at least 26 000 patient-years of follow-up 
had been achieved in the whole trial population. Patients 
were therefore asked to consent to ongoing follow-up 
beyond 5 years until the trial ended.
All data analyses were done according to a pre-
established analysis plan.23,24 Baseline characteristics and 
laboratory data were tabulated according to the assigned 
treatment groups, and were expressed as proportions for 
categorical variables and as means (SD) for continuous 
variables with a normal distribution.
All patients randomly allocated to a group were 
included in the primary analysis.31 We used Kaplan-Meier 
methods to construct cumulative time-to-event curves for 
the two groups, with a comparison by use of the log-rank 
test.32 We used a Cox proportional hazard model analysis 
to control for any potential imbalance in baseline 
characteristics and follow-up between the two groups.33 
We also used a random eﬀ ects model (frailty model) to 
investigate the possible inﬂ uence of any variation in 
treatment eﬀ ect among the various centres.33
B vitamins (n=4089) Placebo (n=4075) Total (n=8164)
Total Value Total Value Total Value
Age 4089 62·5 (12·6) 4075 62·6 (12·4) 8164 62·6 (12·5)
Men 4089 2614 (64%) 4075 2604 (64%) 8164 5218 (64%)
Ethnic group
White 3916 1638 (42%) 3898 1638 (42%) 7814 3276 (42%)
East and southeast Asian 3916 956 (24%) 3898 957 (25%) 7814 1913 (24%)
South Asian 3916 1037 (26%) 3898 1016 (26%) 7814 2053 (26%)
Other 3916 285 (7%) 3898 287 (7%) 7814 572 (7%)
Oxfordshire classiﬁ cation of stroke subtype
Total anterior circulation 
syndrome 
4011 90 (2%) 4000 103 (3%) 8011 193 (2%)
Partial anterior circulation 
syndrome 
4011 2153 (54%) 4000 2153 (54%) 8011 4306 (54%)
Lacunar syndrome 4011 1522 (38%) 4000 1513 (38%) 8011 3035 (38%)
Posterior circulation 
syndrome 
4011 246 (6%) 4000 231 (6%) 8011 477 (6%)
Pathological subtype of stroke
Ischaemic stroke
Transient ischaemic 
attack of brain or eye
4049 687 (17%) 4037 715 (18%) 8086 1402 (17%)
Ischaemic stroke 4049 2860 (71%) 4037 2843 (70%) 8086 5703 (71%)
Retinal infarction 4049 7 (0%) 4037 11 (0%) 8086 18 (0%)
Haemorrhagic stroke
Primary intracerebral 
haemorrhage
4049 384 (9%) 4037 358 (9%) 8086 742 (9%)
Subarachnoid 
haemorrhage
4049 32 (1%) 4037 34 (1%) 8086 66 (1%)
Uncertain or unknown 
pathological type 
4049 79 (2%) 4037 76 (2%) 8086 155 (2%)
Cause of ischaemic stroke
Large artery disease 3590 1499 (42%) 3606 1525 (42%) 7196 3024 (42%)
Small artery disease 3590 1374 (38%) 3606 1388 (38%) 7196 2762 (38%)
Embolism from the heart 3590 216 (6%) 3606 186 (5%) 7196 402 (6%)
Uncertain or unknown 
cause
3590 501 (14%) 3606 507 (14%) 7196 1008 (14%)
Severity of qualifying stroke
Independent (Oxford 
handicap score <3) 
3986 3035 (76%) 3967 3024 (76%) 7953 6059 (76%)
Dependent (Oxford 
handicap score ≥3) 
3986 951 (24%) 3967 943 (24%) 7953 1894 (24%)
Past history
Stroke 4035 624 (15%) 4028 658 (16%) 8063 1282 (16%)
Myocardial infarction 4027 298 (7%) 4018 300 (7%) 8045 598 (7%)
Peripheral artery disease 4034 179 (4%) 4023 188 (5%) 8057 367 (5%)
Revascularisation procedure 
of brain, heart, or limbs
4089 275 (7%) 4075 292 (7%) 8164 567 (7%)
History of hypertension 4035 2863 (71%) 4027 2874 (71%) 8062 5737 (71%)
Ever smoked 4032 2011 (50%) 4026 2008 (50%) 8058 4019 (50%)
Hypercholesterolaemia 4026 1333 (33%) 4021 1321 (33%) 8047 2654 (33%)
Diabetes 4039 954 (24%) 4028 945 (23%) 8067 1899 (24%)
Atrial ﬁ brillation 4036 330 (8%) 4027 318 (8%) 8063 648 (8%)
Ischaemic heart disease 3917 658 (17%) 3905 671 (17%) 7822 1329 (17%)
History of depression 3642 273 (8%) 3635 271 (7%) 7278 544 (7%)
Alcohol intake (standard 
drinks [10 g alcohol] per day)
4088 0·8 (2·3) 4074 0·8 (2·6) 8162 0·8 (2·5)
(Continues on next page)
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In prespeciﬁ ed subgroup analyses we compared the 
primary outcome between the placebo group and the 
B vitamins group according to age, sex, ethnic group, 
clinical stroke syndrome, stroke pathology, stroke cause, 
stroke severity, baseline blood creatinine, total 
homocysteine, and vitamin B12 status.24 We also did a 
prespeciﬁ ed secondary on-treatment analysis that 
excluded any patients who did not take any of the trial 
drugs or who did not comply with the protocol. We used 
two-sided signiﬁ cance tests throughout and p 0·05 was 
deemed signiﬁ cant.
This trial is registered with ClinicalTrials.gov, 
NCT00097669, and Current Controlled Trials, 
ISRCTN74743444.
Role of the funding source
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, the 
writing of the report, or in the decision to submit the 
paper for publication. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
Between Nov 19, 1998, and Dec 31, 2008, 8164 patients were 
randomly assigned to receive B vitamins (n=4089) or 
placebo (n=4075; ﬁ gure 1). Demographics and baseline 
characteristics were similar between groups (table 1). 42% 
of patients were white, 24% east or southeast Asian, and 
26% south Asian. The qualifying diagnosis was ischaemic 
stroke in 71% of patients, transient ischaemic attack in 
17%, and intracerebral haemorrhage in 9%. 76% of patients 
were functionally independent (Oxford handicap score ≤2) 
at the time of random allocation.34
Patients were followed up until June 30, 2009, with 
14 182 person-years of follow-up in the B vitamins group 
and 13 997 person-years of follow-up in the placebo 
group. The median duration of follow-up was 3·4 years 
(IQR 2·0–5·5). 7462 (91%) of 8164 patients were followed 
up until the trial ended; 702 patients (9%) were lost to 
follow-up, primarily at three sites (n=392; 56%). The rate 
of loss to ﬁ nal follow-up was 8·7% in the placebo group 
and 8·5% in the B vitamins group (webappendix p 1). 
1543 (38%) of 4079 patients who were randomly assigned 
before June 30, 2004, who had consented to 5 years of 
follow-up, and who were invited to continue follow-up 
beyond 5 years chose to stop the study drug and withdrew 
consent for further follow-up.
The rate of discontinuation of trial drugs increased 
with time, and at the same rate in each treatment group 
(p=0·51). In the ﬁ rst year, 414 (10%) of 4075 patients 
assigned placebo and 436 (11%) of 4089 assigned 
B vitamins had discontinued, and at the end of the trial 
1115 (27%) of 4075 patients in the placebo group and 1148 
(28%) of 4089 in the B vitamins group had discontinued 
(webappendix p 1). 
The composite primary endpoint of non-fatal stroke, 
non-fatal myocardial infarction, or vascular death 
occurred in 616 (15%) of 4089 patients in the B vitamins 
group (4·3% per year) and in 678 (17%) of 4075 patients 
B vitamins (n=4089) Placebo (n=4075) Total (n=8164)
Total Value Total Value Total Value
(Continued from previous page)
Laboratory results
Creatinine (μmol/L) 2214 92·4 (40·3) 2180 91·4 (34·6) 4394 91·9 (37·6)
Vitamin B12 (pmol/L) 243 320 (166) 251 325 (197) 494 322 (182)
Vitamin B6 (nmol/L) 208 40·5 (21·2) 204 38·7 (19·0) 412 39·6 (20·1)
Red cell folate (nmol/L) 209 962 (495) 202 881 (453) 411 922 (476)
Fasting homocysteine 
(μmol/L)
604 14·4 (9·2) 601 14·2 (7·7) 1205 14·3 (8·5)
Creatinine >120 μmol/L* 2214 253 (11%) 2180 240 (11%) 4394 493 (11%)
Median vitamin B12 
≤287 pmol/L†
243 126 (52%) 251 122 (49%) 494 248 (50%)
Data are mean (SD) or number (%). *Cutoﬀ  value chosen because 120 μmol/L is the upper limit of normal in many 
laboratories. †Cutoﬀ  value chosen because 287 pmol/L was the median value. 
Table 1: Demographics and baseline characteristics
B vitamins 
(n=4089)
Placebo 
(n=4075)
Risk ratio 
(95% CI)
p value*
Primary
Stroke, myocardial infarction, or vascular death 616 (15%) 678 (17%) 0·91 (0·82–1·00) 0·05
Secondary
Stroke 360 (9%) 388 (10%) 0·92 (0·81–1·06) 0·25
Myocardial infarction 118 (3%) 114 (3%) 1·03 (0·80–1·33) 0·86
Vascular death 328 (8%) 380 (9%) 0·86 (0·75–0·99) 0·04
Non-vascular death 267 (7%) 231 (6%) 1·15 (0·97–1·37) 0·14
Death from any cause 614 (15%) 633 (16%) 0·97 (0·87–1·07) 0·49
Stroke, myocardial infarction, or any death 851 (21%) 887 (22%) 0·96 (0·88–1·04) 0·26
Revascularisation procedure 122 (3%) 113 (3%) 1·08 (0·84–1·38) 0·57
Stroke, myocardial infarction, vascular death, or 
revascularisation 
684 (17%) 740 (18%) 0·92 (0·84–1·01) 0·09
Data are number (%). Only the ﬁ rst event was used for each type of event. One patient could have multiple diﬀ erent 
types of event, so the sum of myocardial infarction, stroke, and death could be more than the total of the primary 
outcome. *Log-rank test.
Table 2: Eﬃ  cacy outcomes
Figure 2: Kaplan-Meier estimates of the composite primary outcome
Risk ratio 0·91 (95% CI 0·82–1·00).
Placebo
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in the placebo group (4·8% per year; RR 0·91, 95% CI 
0·82 to 1·00; p=0·05; absolute risk reduction 1·56%, 
95% CI –0·01 to 3·16; table 2; ﬁ gure 2). A Cox proportional 
hazard model analysis revealed similar hazard ratios to 
the RR, both before (0·90, 95% CI 0·81 to 1·00) and after 
(0·91, 0·81 to 1·03) adjusting for any potential imbalance 
in the baseline characteristics and follow-up duration 
between the two groups. In a random eﬀ ects (frailty) 
model that was ﬁ tted to take into account any variation in 
treatment eﬀ ect between centres, the ﬁ xed treatment 
eﬀ ect (hazard ratio 0·90, 95% CI 0·81 to 1·00) was 
consistent with that derived from the Cox model.
Compared with placebo, treatment with B vitamins was 
not associated with a signiﬁ cant reduction in the RR for 
non-fatal or fatal stroke (p=0·25), non-fatal or fatal 
myocardial infarction (p=0·86), or death from any cause 
(p=0·49) but was associated with a signiﬁ cant reduction 
in death from vascular causes (p=0·04; table 2). For the 
prespeciﬁ ed subgroups, there was no inconsistency or 
signiﬁ cant interaction with the overall treatment eﬀ ect of 
B vitamins (ﬁ gure 3).
Among 1164 patients who had a fasting blood test at 
the end of follow-up, the mean total homocysteine 
concentration was 10·5 μmol/L (SD 4·9) in the 
Figure 3: Eﬀ ects of B vitamins on the primary outcome in prespeciﬁ ed subgroups
TACS=total anterior circulation syndrome. PACS=partial anterior circulation syndrome. LACS=lacunar syndrome. POCS=posterior circulation syndrome. TIA=transient 
ischaemic attack. ICH=intracerebral haemorrhage. SAH=subarachnoid haemorrhage. Oxford score=Oxford handicap score.34 tHCY=total homocysteine. To convert 
values for creatinine from mmol/L to mg/L, divide by 88·4. To convert values for vitamin B12 from pmol/L to pg/mL, divide by 0·7378. To convert values for 
homocysteine from μmol/L to mg/L, divide by 7·396.
Age ≤60 years 1720 174 (10%)  1690 193 (11%) 0·89 (0·73–1·08) 0·77
Age >60 years 2369 442 (19%) 2385 485 (20%) 0·92 (0·82–1·03)
Men 2614 411 (16%) 2604 436 (17%) 0·94 (0·83–1·06) 0·34
Women 1475 205 (14%) 1471 241 (16%) 0·85 (0·71–1·01)
White 1638 264 (16%) 1638 289 (17%) 0·91 (0·78–1·06) 0·88
East and southeast Asian 956 155 (16%) 957 176 (18%) 0·88 (0·72–1·07)
South Asian 1037 103 (10%) 1016 115 (11%) 0·88 (0·68–1·13)
Other 285 59 (21%) 287 59 (21%) 1·01 (0·73–1·39)
TACS 90 16 (18%) 103 25 (24%) 0·73 (0·42–1·28) 0·16
PACS 2153 339 (16%) 2153 339 (15%) 1·00 (0·87–1·15)
LACS 1522 210 (14%) 1513 257 (17%) 0·81 (0·69–0·96)
POCS 246 37 (15%) 231 44 (19%) 0·79 (0·53–1·18)
TIA 687 69 (10%) 715 100 (14%) 0·72 (0·54–0·96) 0·06
Ischaemic stroke 2860 480 (17%) 2843 489 (17%) 0·98 (0·87–1·09)
Primary ICH 384 45 (12%) 358 64 (18%) 0·66 (0·46–0·93)
SAH 32 3 (9%) 34 3 (19%) 1·06 (0·23–4·89)
Large artery disease 1499 279 (19%) 1525 263 (17%) 1·08 (0·93–1·26) 0·07
Small artery disease 1374 190 (14%) 1388 239 (17%) 0·80 (0·67–0·96)
Embolism from heart 216 49 (23%) 186 48 (26%) 0·88 (0·62–1·24)
Uncertain cause 501 36 (7%) 507 46 (9%) 0·79 (0·52–1·20)
Oxford score <3 3035 428 (14%) 3024 456 (15%) 0·94 (0·83–1·06) 0·19
Oxford score ≥3 951 171 (18%) 943 206 (22%) 0·82 (0·69–0·99)
Creatinine ≤120 mmol/L 1961 287 (15%) 1940 342 (18%) 0·83 (0·72–0·96) 0·80
Creatinine >120 mmol/L 253 59 (23%) 240 63 (26%) 0·89 (0·65–1·21)
Vitamin B12 ≤287 pmol/L 126 32 (25%) 122 31 (25%) 1·00 (0·65–1·53) 0·15
Vitamin B12 >287 pmol/L 117 19 (16%) 129 30 (23%) 0·70 (0·42–1·17)
 
tHCY <11 μmol/L 210 24 (11%) 202 37 (18%) 0·62 (0·39–1·00) 0·15
tHCY 11–14 μmol/L 177 42 (24%) 164 36 (22%) 1·08 (0·73–1·60)
tHCY >14 μmol/L 217 43 (20%) 235 54 (23%) 0·86 (0·60–1·23)
B vitamins
n Event rate (%) n Event rate (%)
Placebo Risk ratio (95% CI) p value
Favours treatment
0·25 0·5 1·0 2·0 4·0
Favours placebo
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B vitamins group and 14·3 μmol/L (6·1) in the placebo 
group (diﬀ erence 3·8 μmol/L, 95% CI 3·1–4·4; 
p<0·0001). The blood samples were taken mainly in 
Australia (438 patients; 38%), Singapore (344; 30%), 
and Austria (157; 13%). The eﬀ ect of B vitamins on total 
homocysteine was similar in patients from these 
countries and those from other countries (data 
not shown).
925 patients had a fasting blood test for total 
homocysteine at both baseline and follow-up. Total homo-
cysteine decreased by a mean of 1·09 (SD 5·5) μmol/L 
between baseline and follow-up, and 198 patients reached 
the primary endpoint. Cox regression analysis revealed 
that for every 1·0 μmol/L decrease in total homocysteine, 
the risk of the primary outcome decreased by 2·0% 
(95% CI –0·5 to 4·3; hazard ratio 0·98, 95% CI 0·96 to 
1·01; p=0·11).
In a post-hoc secondary exploratory analysis that 
excluded the three sites from which 56% of the patients 
were lost to follow-up, the unadjusted relative risk of the 
primary outcome for the remaining 6789 patients was 
0·91 (95% CI 0·81–1·01; p=0·073) and the adjusted RR 
was 0·91 (95% CI 0·80–1·03; p=0·14), which was 
consistent with that for the whole trial population. The 
results of the on-treatment analysis—which excluded 
351 patients because of a protocol violation or because 
the patient did not take any of the trial drugs—were also 
consistent with the results from the whole trial population 
(webappendix p 2).
Vitamin B12 deﬁ ciency was diagnosed during follow-
up in none of the 4089 patients in the B vitamins group 
compared with six (0·1%) of 4075 patients in the placebo 
group (p=0·02). Peripheral neuropathy suspected to be 
caused by vitamin B6 toxicity was diagnosed in ﬁ ve 
patients assigned to B vitamins (0·1%) compared with 
nine patients assigned to placebo (0·2%; p=0·30). There 
were no unexpected serious and non-serious adverse 
events and there were no signiﬁ cant diﬀ erences in 
common adverse eﬀ ects between the treatment groups 
(data not shown). 
Discussion
In the VITATOPS trial, daily treatment with the 
combination of folic acid, vitamin B6, and vitamin B12 
after a recent stroke or transient ischaemic attack was 
safe but was not signiﬁ cantly more eﬀ ective than placebo 
in reducing the incidence of major vascular events. Our 
results are generalisable because we included a large 
number of patients from various ethnic groups from 
around the world who were not exposed to mandatory 
background fortiﬁ cation of food with folic acid. 
On the basis of an interpretation of the epidemiological 
evidence available when we designed the study,2,5,23,24 we 
hypothesised that daily supplementation with B vitamins 
would reduce total homocysteine by a quarter to a third 
(eg, by 3–4 μmol/L, from about 12 μmol/L to 8–9 μmol/L) 
and reduce the relative risk of the composite endpoint of 
stroke, myocardial infarction, or vascular death by 15%. 
Figure 4: Eﬀ ects of treatment with B vitamins on the composite of non-fatal stroke, non-fatal myocardial infarction, or death due to vascular causes
All trials were looking at ﬁ rst stroke, with the exception of the VISP trial and the VITATOPS trial, which included patients with a previous stroke. M-H=Mantel-Haenszel. 
*Data are for major vascular events as deﬁ ned by the composite of stroke, coronary events, vascular death, and revascularisation procedures. 
B vitamins versus placebo
ASFAST, 200614 156 33 (21%) 159 40 (25%) 0·84 (0·56–1·26)
HOPE-2, 200615 2758 519 (19%) 2764 547 (20%) 0·95 (0·85–1·06)
NORVIT, 200616 2806 544 (19%) 943 172 (18%) 1·06 (0·91–1·24)
WAFACS, 200818 2721 205 (75%) 2721 211 (8%) 0·97 (0·81–1·17)
SEARCH,* 201020 6033 1537 (25%) 6031 1493 (25%) 1·03 (0·97–1·09)
VITATOPS, 2010 4089 616 (15%) 4075 678 (17%) 0·91 (0·82–1·00)
Subtotal 18 563 3454 (19%) 16 693 3141 (19%) 0·99 (0·94–1·03)
Heterogeneity: χ2=6·59, df=5 (p=0·25); I2=24%
Test for overall eﬀect: Z=0·61 (p=0·54)
High-dose B vitamins versus low-dose B vitamins
VISP, 20046 1827 303 (17%) 1853 316 (17%) 0·97 (0·84–1·12)
Subtotal 1827 303 (17%) 1853 316 (17%) 0·97 (0·84–1·12)
Heterogeneity: not applicable
Test for overall eﬀect: Z=0·38 (p=0·70)
Total (95% CI) 20 390 3757 (18%) 18 546 3457 (19%) 0·99 (0·94–1·03)
Heterogeneity: χ2=6·64, df=6 (p=0·36); I2=10%
Test for overall eﬀect: Z=0·70 (p=0·49)
Test for subgroup diﬀerences: not applicable
B vitamins
n Event rate (%) n Event rate (%)
Control Risk ratio M–H, ﬁxed (95% CI)
Favours experimental
0·7 1 1·5
Favours control
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Estimates from meta-analyses—which were published 
after the design of this trial—of prospective observational 
studies and genotype-disease association studies 
suggested that lowering total homocysteine by 3 μmol/L 
would reduce the relative risk of stroke by about 24% 
(15–33%) and myocardial infarction by 16% (11–20%).3,4
Of the 1164 patients who volunteered to have their total 
homocysteine measured at ﬁ nal follow-up, patients in the 
B vitamins group had a similar reduction in total homo-
cysteine compared with placebo (3·8 μmol/L, 95% CI 
3·1–4·4 μmol/L) to that suggested in our hypothesis. The 
homocysteine-lowering eﬀ ect of the B vitamins was 
consistent among diﬀ erent ethnic groups.35,36
The annual rate of primary outcomes among patients 
assigned to placebo was lower (4·8% per year) than 
expected (8·0% per year), but after prolonged recruitment 
and follow-up (28 179 patient-years) the number of 
primary outcome events (n=1294) was suﬃ  cient for the 
trial to be adequately powered to identify or exclude (with 
95% conﬁ dence) a 15% reduction in relative risk of the 
primary outcome with B vitamins compared with 
placebo. However, we reported only a 9% reduction in 
the RR of the primary outcome with B vitamins compared 
with placebo. The 95% CIs suggest that B vitamins might 
reduce the risk of the primary outcome by as much as 
18% or as little as 0% compared with placebo. Therefore, 
our ﬁ ndings do not deﬁ nitively conﬁ rm that 
supplementation with B vitamins has a clinically 
signiﬁ cant beneﬁ cial eﬀ ect on major vascular events.
Results from our subgroup analysis suggest that 
supplementation with B vitamins might reduce the risk 
of stroke, myocardial infarction, or vascular death in 
patients with symptomatic small vessel disease of the 
brain causing lacunar infarction or intracerebral 
haemorrhage. This reduction has also been suggested by 
other investigators who reported that homocysteine is a 
risk factor for cerebral small vessel disease.28,29 If validated, 
this ﬁ nding could explain any apparent diﬀ erential eﬀ ect 
Figure 5: Eﬀ ects of treatment with B vitamins on stroke
All trials were looking at ﬁ rst stroke, with the exception of the VISP trial and the VITATOPS trial, which included patients with a previous stroke. M-H=Mantel-Haenszel.
B vitamins
n Event rate (%) n Event rate (%)
Control Risk ratio M–H, ﬁxed (95% CI)
Favours experimental
0·2 0·5 1 2 5
Favours control
B vitamins versus placebo
MARK, 19968 1657 22 (1%) 1661 35 (2%) 0·63 (0·37–1·07)
Liem, 200310 300 8 (3%) 293 12 (4%) 0·65 (0·27–1·57)
Righetti, 200613 37 1 (3%) 51 2 (4%) 0·69 (0·06–7·32)
ASFAST, 200614 156 8 (5%) 159 18 (11%) 0·45 (0·20–1·01)
HOPE-2, 200615 2758 111 (4%) 2764 147 (5%) 0·76 (0·59–0·96)
NORVIT, 200616 2806 71 (3%) 2764 174 (5%) 0·88 (0·57–1·37)
HOST, 200717 1032 37 (4%) 1024 41 (4%) 0·90 (0·58–1·38)
WAFACS, 200818 2721 79 (3%) 2721 69 (3%) 1·14 (0·83–1·57)
WENBIT, 200819 2311 48 (2%) 779 19 (2%) 0·85 (0·50–1·44)
SEARCH, 201020 6033 269 (4%) 6031 265 (4%) 1·01 (0·86–1·20)
House, 201021 119 6 (5%) 119 1 (1%) 6·00 (0·73–49·08)
VITATOPS, 2010 4089 360 (9%) 4075 388 (10%) 0·92 (0·81–1·06) 
Subtotal 24 019 1020 (4%) 20 620 1024 (5%) 0·92 (0·84–1·00)
Heterogeneity: χ2=14·48, df=11 (p=0·21); I2=24%
Test for overall eﬀect: Z=2·00 (p=0·05)
B vitamins versus standard care
FOLARDA, 200411 140 1 (1%) 143 0 (0%) 3·06 (0·13–74·58)
Subtotal 140 1 (1%) 143 0 (0%) 3·06 (0·13–74·58)
Heterogeneity: not applicable
Test for overall eﬀect: Z=0·69 (p=0·49)
High-dose B vitamins versus low-dose B vitamins
VISP, 20046 1827 152 (8%) 1853 148 (8%) 1·04 (0·84–1·29)
Wrone, 200412 342 19 (6%) 168 8 (5%) 1·17 (0·52–2·61)
Subtotal 2169 171 (8%) 2021 156 (8%) 1·05 (0·85–1·29)
Heterogeneity: χ2=0·07, df=1 (p=0·79); I2=0%
Test for overall eﬀect: Z=0·46 (p=0·65)
Total (95% CI) 26 328 1192 (5%) 22 784 118 (5%) 0·94 (0·86–1·01)
Heterogeneity: χ2=16·46, df=14 (p=0·29); I2=15%
Test for overall eﬀect: Z=1·66 (p=0·10)
Test for subgroup diﬀerences: not applicable
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of homocysteine lowering on small vessel ischaemic 
stroke compared with large artery ischaemic stroke and 
myocardial infarction.
The main limitations of our trial, which could introduce 
bias, were incomplete adherence to trial drugs and 
incomplete follow-up. The high, yet similar, rates of non-
adherence in each treatment group mean that any true 
treatment diﬀ erences between the two groups would 
have been minimised, thus biasing the results to the 
null. Because of the high, yet similar, rates of loss to 
follow-up in each treatment group, small diﬀ erences in 
event rates among patients lost to follow-up could have 
markedly aﬀ ected the results of the trial. If we assume an 
absence of treatment eﬀ ect of B vitamins among patients 
who were lost to follow-up and impute identical primary 
outcome event rates in each treatment group for those 
who were lost to follow-up, the relative risk for the 
primary outcome event would have been 0·92 (95% CI 
0·83–1·01; p=0·08). If the primary outcome event rates 
of those lost to follow-up were consistent with the overall 
trial population, the relative risk for the primary event 
would have been 0·90 (95% CI 0·82–0·99; p=0·04). We 
found no evidence of a variation in treatment eﬀ ect 
among centres in the random eﬀ ects (frailty) model. If 
we exclude the three centres that accounted for 56% of 
the loss to follow-up, the results are similar to those of 
the whole trial population. The results of our on-
treatment analysis were also consistent with our primary 
analysis, but they had less statistical power.
Another potential limitation of our trial is that the 
median duration of adherence to treatment was 2·8 years 
and the median duration of follow-up was 3·4 years, 
which might not have been long enough to adequately 
identify or exclude any long-term eﬀ ects of B vitamins.
To minimise random error, we added our data to other 
randomised controlled trials of homocysteine-lowering 
therapy in patients with or without pre-existing 
cardiovascular disease (ﬁ gures 4–6).6,8–22 The updated meta-
analysis suggests that B vitamins are not signiﬁ cantly 
more eﬀ ective than control treatments in reducing the 
Figure 6: Eﬀ ects of treatment with B vitamins on myocardial infarction 
M-H=Mantel-Haenszel. 
B vitamins
n Event rate (%) n Event rate (%)
Control Risk ratio M–H, ﬁxed (95% CI)
Favours experimental
0·2 0·5 21 5
Favours control
B vitamins versus placebo
CHAOS, 20029 942 23 (2%) 940 12 (1%) 1·91 (0·96–3·82)
HOPE-2, 200615 2758 341 (12%) 2764 349 (13%) 0·98 (0·85–1·13)
NORVIT, 200616 2806 490 (17%) 943 153 (16%) 1·08 (0·91–1·27)
HOST, 200717 1032 129 (13%) 1024 150 (15%) 0·85 (0·69–1·06)
WAFACS, 200818 2721 65 (2%) 2721 74 (3%) 0·88 (0·63–1·22)
WENBIT, 200819 2311 190 (8%) 779 58 (7%) 1·10 (0·83–1·46)
SEARCH, 201020 6033 431 (7%) 6031 429 (7%) 1·00 (0·88–1·14)
House, 201021 119 8 (7%) 119 4 (4%) 2·00 (0·62–6·46)
VITATOPS, 2010 4089 118 (3%) 4075 114 (3%) 1·03 (0·80–1·33) 
Subtotal 22 811 1795 (8%) 19 396 1343 (7%) 1·01 (0·94–1·08)
Heterogeneity: χ2=8·69, df=8 (p=0·37); I2=8%
Test for overall eﬀect: Z=0·17 (p=0·87)
B vitamins versus standard care
FOLARDA, 200411 140 8 (6%) 143 10 (7%) 0·82 (0·33–2·01)
Liem, 200310 300 3 (1%) 293 4 (1%) 0·73 (0·17–3·24)
Subtotal 440 11 (3%) 436 14 (3%) 0·79 (0·37–1·71)
Heterogeneity: χ2=0·02, df=1 (p=0·90); I2=0%
Test for overall eﬀect: Z=0·59 (p=0·55)
High-dose B vitamins versus low-dose B vitamins
VISP, 20046 1814 72 (4%) 1835 81 (4%) 0·90 (0·33–2·01)
Wrone, 200412 342 9 (3%) 168 4 (2%) 1·11 (0·35–3·54)
Subtotal 2156 81 (4%) 2003 85 (4%) 0·91 (0·68–1·23)
Heterogeneity: χ2=0·11, df=1 (p=0·74); I2=0%
Test for overall eﬀect: Z=0·60 (p=0·55)
Total (95% CI) 25 407 1887 (7%) 21 835 1442 (7%) 1·00 (0·93–1·07)
Heterogeneity: χ2=9·54, df=12 (p=0·66); I2=0%
Test for overall eﬀect: Z=0·03 (p=0·97)
Test for subgroup diﬀerences: not applicable
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risk of the composite of stroke, myocardial infarction, or 
vascular death (0·99, CI 0·94–1·03, p=0·49; ﬁ gure 4); 
stroke (RR 0·94, 95% CI 0·86–1·01; p=0·10; ﬁ gure 5); or 
myocardial infarction (1·00, 0·93–1·07; p=0·97; ﬁ gure 6).
A planned meta-analysis of individual data from all 
previous, and three ongoing, randomised controlled trials 
of B vitamins will provide more reliable estimates of the 
long-term eﬀ ects of B vitamins in the prevention of stroke 
and other major vascular events among patients with 
stroke or transient ischaemic attack, particularly when 
caused by symptomatic cerebral small vessel disease (deep 
intracerebral haemorrhage and lacunar infarction).37–40
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Research in context
Systematic review
We searched the Cochrane Central Register of Controlled 
Trials (CENTRAL) on the Cochrane Library (issue 1, 2010), 
Medline (1950–2010), Embase (1988–2010), ISI Web of 
Science (1993–2010), and the Cochrane Stroke Group 
Specialised Register (2010). We also hand-searched relevant 
journals and the reference lists of included papers. We 
included randomised clinical trials assessing the eﬀ ects of 
B vitamins (folic acid, vitamin B12, and vitamin B6) in 
lowering blood concentrations of homocysteine and 
preventing stroke and other major cardiovascular events. We 
assessed papers with stroke, myocardial infarction, and death 
attributable to vascular causes as the primary outcomes.
Interpretation
The VITATOPS trial shows, for the ﬁ rst time, that B vitamins 
are safe but not signiﬁ cantly more eﬀ ective than placebo in 
reducing the risk of major vascular events among patients 
with a history of recent stroke or transient ischaemic attack. 
These results are consistent with trials of B vitamins in other 
patient populations.
Articles
864 www.thelancet.com/neurology   Vol 9   September 2010
A Persico (IRCCS C Mondino, Pavia, 16); F Casoni, A Costa*, M Magoni*, 
R Spezi, R Tortorella, E Venturelli, V Vergani (Spedali Civili di Brescia, 
Bresica, 9); S Caprioli, M Provisione, D Zanotta* (Ospedale di Circolo, 
Busto Arsizio, 5); Malaysia J M Abdullah*, T Damitri, B Idris*, S Sayuthi 
(Hospital Universiti Sains of Malaysia, Kubang Kerian, 68); J J H Hong, 
C T Tan, K S Tan† (University of Malaya Medical Centre, Kuala Lumpur, 
Selangor, 13); Moldova G Dutca, V Grigor, S Groppa†, D Manea (City 
Emergency Hospital, Chisinau, 114); Netherlands S Achterberg, A Algra†, 
P H A Halkes, L J Kappelle* (University Medical Center Utrecht, 
Utrecht, 61); A M Boon, J C Doelman, R Sips*, F Visscher 
(Oosterscheldeziekenhuis, Goes, 37); V I H Kwa*, O A Ternede, 
J J van der Sande (Slotervaartziekenhuis, Amsterdam, 14); New Zealand 
T Frendin, J Gommans† (Hawke’s Bay Hospital, Napier, 101); 
N E Anderson*, P Bennett, A Charleston, D Spriggs (Auckland City 
Hospital, Auckland, 62); J Singh* (North Shore Hospital, North Shore, 12); 
J Bourke*, R Bucknell (Palmerston North Hospital, Palmerston North, 6); 
H McNaughton* (Wellington Hospital, Wellington, 3); Pakistan A Anwar, 
H Murtaza, W Uddin† (Pakistan Ordinance Factories Hospital, Wah Cantt, 
Wah, 140); J Ismail* (Dow University of Health Sciences Civil Hospital, 
Karachi, 89); N U Khan* (KRL University, Islamabad, 2); Philippines 
J C Navarro† (Jose R Reyes Memorial Medical Center, Manila, 411); 
V G Amor, M T Canete*, C Lim, E B Ravelo, M Siguenza, 
M O Villahermosa (Chong Hua Hospital, Cebu City, 137); M T Canete*, 
M J T Cardino, R Cenabre, M Gara, Z Salas (Cebu Velez General Hospital/
Visayas Community Medical Center, Cebu City, 126); A Batac, 
M T Canete*, L Conde, P Dumdum, F S Garcia, S Libarnes, N Matig-a, 
N Olanda (Cebu Doctor’s Hospital, Cebu City, 113); R Arcenas, 
M T Canete*, A Loraña (Vicente Sotto Memorial Medical Center, Cebu 
City, 104); A Surdilla* (Cagayan de Oro Medical Center, Cebu City, 32); 
M L Araullo, J Lokin* (University of Santo Tomas Hospital, Manila, 13); 
G Maylem* (Cagayan Valley Medical Center, Tuguegarao, 1); Portugal 
E Marques, M Veloso* (Hospital Distrital Oliveira de Azeméis, Oliveira de 
Azeméis, 61); M Correia†, G Lopes (Hospital Geral de Santo António, 
Porto, 35); P Canhão, J M Ferro†, T P Melo (Hospital de Santa Maria, 
Porto, 27); A Dias, A P Sousa* (Hospital Visconde de Salreu, Estarreja, 13); 
Georgia A Tsiskaridze†, T Vashadze (Sarajishvili Institute of Neurology, 
Tbilisi, 118); Serbia I Divjak† (University of Novi Sad [Neurology], Novi Sad, 
67); I Divjak†, V Papic (University of Novi Sad [Neurosurgery], Novi Sad, 
40); Singapore H M Chang, C P L H Chen†, D A De Silva, E K Tan*, 
M C Wong (Singapore General Hospital, 875); Sri Lanka U K Ranawaka†, 
J C Wijesekera (National Hospital of Sri Lanka, Colombo, 274); 
H A de Silva*, U K Ranawaka†, C N Wijekoon (University of Kelaniya, 
Columbo, 87); UK J Dawson, P Higgins, K R Lees†, L MacDonald, 
K McArthur, Y McIlvenna, T Quinn, M Walters (Western Inﬁ rmary/
University of Glasgow, Glasgow, 432); R Curless*, J Dickson, J Murdy, 
A Scott (North Tyneside District Hospital, North Shields, Tyne And Wear, 
195); S Cameron, K Darnley, M Dennis*, D Lyle (Western General 
Hospital, Edinburgh, 161); A Hunter, M Watt*, I Wiggam (Royal Victoria 
Hospital, Edinburgh, 118); J Murdy, H Rodgers* (Royal Victoria Inﬁ rmary, 
Newcastle, 97); F Dick, M Macleod, A McKenzie* (Stirling Royal Inﬁ rmary, 
Stirling, 71); P Jones*, S Jones (Bronglais General Hospital, Aberystwyth, 
62); L Caudwell, M Hussain* (Musgrove Park Hospital, Taunton, 62); 
M K Albazzaz*, K Elliott, B Hardware (Barnsley District Hospital, 
Barnsley, 60); E Bacabac, H Martin, A Sharma*, V Sutton (University 
Hospital Aintree, Liverpool, 58); H Baht, L Cowie, G Gunathilagan, 
D R Hargrove, D G Smithard* (William Harvey Hospital, Ashford, Kent, 
58); M Adrian, P Bath*, F Hammonds (Nottingham University Hospitals, 
Nottingham, 51); H Maguire, C Roﬀ e*, J Rushton (University Hospital of 
North Staﬀ ordshire, Stoke-on-Trent, 43); M Datta-chaudhuri, K Diyazee, 
S Krishnamoorthy* (Stepping Hill Hospital, Stockport, 42); K McNulty, 
J Okwera* (Rotherham General Hospital, Rotherham, 39); C Hilaire, 
D Kelly* (Torbay Hospital, Torbay, 38); L Barron, M James*, N Wedge 
(Royal Devon and Exeter Hospital, Exeter, 37); M Bruce, M Macleod* 
(Aberdeen Royal Inﬁ rmary, Aberdeen, 29); M Barber*, D Esson 
(Monklands Hospital, North Lanarkshire, 19); D Ames, J Chataway* 
(St Mary’s Paddington Hospital, London, 17); S Bulley, K Jenkins, 
K Rashed* (Yeovil Hospital, Yeovil, 15); B E A Dafalla*, T C Venugopalan 
(St Luke’s Hospital, Crosland Moor, Huddersﬁ eld, 14); M Ball, 
S Punnoose* (Chesterﬁ eld Hospital, 13); F Justin, L Sekaran*, 
S Sethuraman (Luton and Dunstable NHSFT Hospital, Luton, 13); 
H Goddard, J Howard, J McIlmoyle* (Blackpool Victoria Hospital, 
Blackpool, 11); C Diver-Hall, M McCarron*, M P McNicholl (Altnagelvin 
Hospital, Londonderry, 8); B Clamp, J Hunter, A Oke*, K Weaver (Cannock 
Chase Hospital, Cannock, 7); P Fraser, C McAlpine* (Stobhill Hospital, 
Glasgow, 6); J Chambers*, H Dymond, G Saunders (Weston General 
Hospital, Weston-super-Mare, 6); P Langhorne*, D Stott, F Wright 
(Glasgow Royal Inﬁ rmary, Glasgow, 5); K Adie, R Bland, G Courtauld, 
F Harrington*, A James, A Mate, C Schoﬁ eld, C Wroath (Royal Cornwall 
Hospital, Cornwall, 5); S Duberley, S Punekar* (Royal Preston Hospital, 
Preston, 5); K Niranjan* (Barking Hospital, Redbridge, 1); D Sandler* 
(Birmingham Heartlands Hospital, Birmingham, 1); USA P Krishna, 
M Moussouttas* (JFK Hospital, Atlantis, FL, 21); M A Notestine, A Slivka† 
(Ohio State University Medical Center, Columbus, OH, 15); D Vallini* 
(South Carolina VA Hospital, Columbia, SC, 12); T Hwang*, M Saverance 
(University of South Carolina, Columbia, SC, 7); K Booth*, D Murphy 
(Abington Memorial Hospital, Abington, PA, 4).
*Principal investigator. †National cordinator.
Conﬂ icts of interest
GJH has received payments for serving as a member of the executive 
committees of the ROCKET-AF (Johnson and Johnson), AMADEUS 
(Sanoﬁ -Aventis), and BOREALIS (Sanoﬁ -Aventis) trials; the steering 
committee of the TRA-2P TIMI 50 trial (Schering Plough); the Australian 
Pradaxa (dabigatran) advisory board (Boehringer Ingelheim); a working 
group on stroke and lipid management in Asia (Pﬁ zer); has received 
honoraria for speaking at scientiﬁ c symposia sponsored by Sanoﬁ -Aventis 
and Pﬁ zer Australia; and has received travel and accommodation 
expenses from Sanoﬁ -Aventis. JWE has received consulting fees and 
honoraria for lecturing at sponsored scientiﬁ c symposia from Bristol-
Myers Squibb, Sanoﬁ -Aventis, Eli Lilly, Astra, and Novartis, and has 
received payment for lectures from Bristol-Myers Squibb, Sanoﬁ -Aventis, 
Eli Lilly, and Astra. JWE’s institute has received grants from Bristol-Myers 
Squibb. CC has received payments for serving as national coordinator of 
the PERFORM (Servier) trial, on the data monitoring committee of the 
DU176B-C-J226 (Dai-Ichi) trial, as adviser to the ImpACT-24 (Brainsgate) 
trial, and for being part of a working group on stroke and lipid 
management in Asia (Pﬁ zer), and has received travel and accommodation 
expenses from Moleac to attend the European Stroke Congress. KRL has 
received consultancy payments for serving on data monitoring 
committees for Lundbeck (DIAS-3,4), Boehringer Ingelheim (ECASS-3), 
Ferrer (ICTUS), Photothera (NEST-3), Archemix, Astellas, Mitsubishi, and 
Talecris, the trial endpoint committee for GlaxoSmithKline (RECORD), 
and the trial steering committees for D-Pharm (MACSI) and Servier 
(PERFORM) and has received honoraria for lectures at scientiﬁ c symposia 
sponsored by Ferrer, Boehringer Ingelheim, and Sanoﬁ -Aventis. QY has 
no conﬂ icts of interest. 
Acknowledgments
The VITATOPS trial was funded by grants from the Australia National 
Health and Medical Research Council (project grants 110267, 403913, and 
572632; program grants 251525 and 454417), the UK Medical Research 
Council, the Singapore Biomedical Research Council, the Singapore 
National Medical Research Council, the Australia National Heart 
Foundation, (grants G 99P 0405, G 02P 0735, G 04P 1611), the Royal 
Perth Hospital Medical Research Foundation, and the Health 
Department of Western Australia. The UK Stroke Research Network 
provided support for patient identiﬁ cation and enrolment in the UK. 
Infrastructure support was provided by Royal Perth Hospital, where the 
trial coordinating oﬃ  ce was located and the Pharmacy Department 
stored and dispensed the tablets. Vitamin tablets and matching placebo 
tablets were supplied by Blackmores, Australia. Thanks to our trial 
coordinators Julia Pizzi and Michelle Tang, and to the 8164 patients in 
20 countries who participated in the trial.
References
1 Alberts MJ, Bhatt DL, Mas J-L, et al, for the REduction of 
Atherothrombosis for Continued Health (REACH) Registry 
Investigators. Three-year follow-up and event rates in the 
international REduction of Atherothrombosis for Continued Health 
Registry. Eur Heart J 2009; 30: 2318–26.
2 Eikelboom JW, Hankey GJ, Anand SS, Lofthouse E, Staples N, 
Baker RI. Association between high homocysteine and ischemic 
stroke due to large- and small- artery disease but not other 
etiological subtypes of ischemic stroke. Stroke 2000; 31: 1069–75.
Articles
www.thelancet.com/neurology   Vol 9   September 2010 865
3 Casas JP, Bautista LE, Smeeth L, Sharma P, Hingorani AD. 
Homocysteine and stroke: evidence on a causal link from 
Mendelian randomisation. Lancet 2005; 365: 224–32.
4 Wald DS, Wald NJ, Morris JK, Law M. Folic acid, homocysteine, and 
cardiovascular disease: judging causality in the face of inconclusive 
trial evidence. BMJ 2006; 333: 1114–17.
5 Homocysteine Lowering Trialists’ Collaboration. Lowering blood 
homocysteine with folic acid based supplements: meta-analysis of 
randomised trials. BMJ 1998; 316: 894–98.
6 Toole JF, Malinow R, Chambless L, et al. Lowering homocysteine in 
patients with ischemic stroke to prevent recurrent stroke, 
myocardial infarction and death: the Vitamin Intervention for 
Stroke Prevention (VISP) randomised controlled trial. JAMA 2004; 
291: 565–75.
7 Spence DL, Bang H, Chambless LE, Stampfer MJ. Vitamin 
intervention for stroke prevention trial: an eﬃ  cacy analysis. Stroke 
2005; 36: 2404–09.
8 Mark SD, Wang W, Fraumeni JF Jr, et al. Lowered risks of 
hypertension and cerebrovascular disease after vitamin/mineral 
supplementation: the Linxian Nutrition Intervention Trial. 
Am J Epidemiol 1996; 143: 658–64.
9 Baker F, Picton D, Blackwood S, et al. Blinded comparison of folic 
acid and placebo in patients with ischaemic heart disease: an 
outcome trial. Circulation 2002; 106 (suppl 2): 741.
10 Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, Jukema JW, 
van Veldhuisen DJ. Secondary prevention with folic acid: eﬀ ects on 
clinical outcomes. J Am Coll Cardiol 2003; 41: 2105–13.
11 Liem AH, van Boven AJ, Veeger GM, et al, for the FOLic Acid on 
RIsk Diminishment after Acute myocardial infarction (FOLARDA). 
Eﬃ  cacy of folic acid when added to statin therapy in patients with 
hypercholesterolemia following acute myocardial infarction: a 
randomised pilot trial. Int J Cardiol 2004; 93: 175–79.
12 Wrone EM, Hornberger JM, Sehnder JL, McCann LM, Coplon NS, 
Fortmann SP. Randomised trial of folic acid for prevention of 
cardiovascular events in end-stage renal disease. J Am Soc Nephrol 
2004; 15: 420–26.
13 Righetti M, Serbelloni P, Milani S, Ferrario G. 
Homocysteine-lowering vitamin B treatment decreases 
cardiovascular events in haemodialysis patients. 
Blood Purif 2006; 24: 379–86.
14 Zoungas S, McGrath BP, Branley P, et al. Cardiovascular 
morbidity and mortality in the atherosclerosis and folic acid 
supplementation trial (ASFAST) in chronic renal failure: a 
multicentre, randomised, controlled trial. J Am Coll Cardiol 2006; 
47: 1108–16.
15 Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with 
folic acid and B vitamins in vascular disease. N Engl J Med 2006; 
354: 1567–77.
16 Bonaa KH, Njolstad I, Ueland PM, et al. Homocysteine lowering 
and cardiovascular events after acute myocardial infarction. 
N Engl J Med 2006; 354: 1578–88.
17 Jamison RL, Hartigan P, Kaufman JS, et al, Veterans Aﬀ airs Site 
Investigators. Eﬀ ect of homocysteine lowering on mortality and 
vascular disease in advanced chronic kidney disease and end-stage 
renal disease: a randomised controlled trial. JAMA 2007; 
298: 1163–70.
18 Albert CM, Cook NR, Gaziano JM, et al. Eﬀ ect of folic acid and 
B vitamins on risk of cardiovascular events and total mortality 
among women at high risk for cardiovascular disease: a 
randomized trial. JAMA 2008; 299: 2027–36.
19 Ebbing M, Bleie Ø, Ueland PM, et al. Mortality and cardiovascular 
events in patients treated with homocysteine-lowering B vitamins 
after coronary angiography: a randomized controlled trial. JAMA 
2008; 300: 795–804.
20 Study of the Eﬀ ectiveness of Additional Reductions in Cholesterol 
and Homocysteine (SEARCH) Collaborative Group. Eﬀ ects of 
homocysteine-lowering with folic acid plus vitamin B12 vs placebo 
on mortality and major morbidity in myocardial infarction 
survivors. JAMA 2010; 303: 2486–94.
21 House AA, Eliasziw M, Cattran DC, et al. Eﬀ ect of B-vitamin therapy 
on progression of diabetic nephropathy. JAMA 2010; 303: 1603–09.
22 Martí-Carvajal AJ, Solà I, Lathyris D, Salanti G. Homocysteine 
lowering interventions for preventing cardiovascular events. 
Cochrane Database Syst Rev 2009; 4: CD006612.
23 The VITATOPS Trial Study Group. The VITATOPS (VITAmins To 
Prevent Stroke) trial: rationale and design of an international, large, 
simple, randomised trial of homocysteine-lowering multivitamin 
therapy in patients with recent transient ischemic attack or stroke. 
Cerebrovasc Dis 2002; 13: 120–26.
24 The VITATOPS Trial Study Group. The VITAmins TO Prevent 
Stroke (VITATOPS) trial: rationale and design of a randomised trial 
of B-vitamin therapy in patients with recent transient ischemic 
attack or stroke (NCT00097669) (ISRCTN74743444). Int J Stroke 
2007; 2: 144–50.
25 Anonymous. Nuremberg Doctors Trial. Declaration of Helsinki 
(1964). BMJ 1996; 313: 1448–49.
26 Schulz KF, Altman DG, Moher D, Fergusson D. CONSORT 2010 
changes and testing blindness in RCTs. Lancet 2010; 375: 1144–46.
27 Warlow CP, Dennis MS, van Gijn J, et al. Stroke. A practical guide 
to management. 2nd edn. Oxford, UK: Blackwell Science, 2000.
28 Hassan A, Hunt BJ, O’Sullivan M, et al. Homocysteine is a risk 
factor for cerebral small vessel disease, acting via endothelial 
dysfunction. Brain 2004; 127: 212–19.
29 Spence JD. Homocysteine-lowering therapy: a role in stroke 
prevention? Lancet Neurol 2007; 6: 830–38.
30 CAPRIE Steering Committee. A randomised, blinded, trial of 
clopidogrel versus aspirin in patients at risk of ischemic events 
(CAPRIE). Lancet 1996; 348: 1329–39.
31 Nuesch E, Trelle S, Reichenback S, et al. The eﬀ ects of excluding 
patients from the analysis in randomised controlled trials: 
meta-epidemiological study. BMJ 2009; 339: b3244.
32 Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event 
outcomes in clinical trials: good practice and pitfalls. Lancet 2002; 
359: 1686–89.
33 Therneau TM, Grambsch PM. Modeling survival data: extending 
the Cox model (Statistics for Biology and Health). New York, USA: 
Springer, 2001. 
34 Bamford JM, Sandercock PA, Warlow CP, Slattery J. Interobserver 
agreement for the assessment of handicap in stroke patients. Stroke 
1989; 20: 828.
35 Hankey GJ, Eikelboom JW, Loh K, et al. Is there a power shortage in 
clinical trials testing the “homocysteine hypothesis”? Preliminary 
results from the VITAmins TO Prevent Stroke (VITATOPS) trial. 
Arterioscler Thromb Vasc Biol 2004; 24: e147.
36 Kasiman K, Eikelboom JW, Hankey GJ, et al. Ethnicity does not 
aﬀ ect the homocysteine-lowering eﬀ ect of B-vitamin therapy in 
Singaporean stroke patients. Stroke 2009; 40: 2209–11.
37 B-Vitamin Treatment Trialists’ Collaboration. Homocysteine-
lowering trials for prevention of vascular disease: protocol for 
collaborative meta-analysis. Clin Chem Lab Med 2007; 45: 1571–76.
38 Bostom AG, Carpenter MA, Hunsicker L, et al. Baseline 
characteristics of participants in the folic acid for vascular outcome 
reduction in transplantation (FAVORIT) trial. Am J Kidney Dis 2009; 
53: 121–28.
39 Galan P, Briancon S, Blacher J, Czernichow S, Hercberg S. The 
SU.FOL.OM3 Study: a secondary prevention trial testing the impact 
of supplementation with folate and B vitamins and/or Omega-3 
PUFA on fatal and non fatal cardiovascular events, design, methods 
and participants characteristics. Trials 2008; 9: 1–9. 
40 China Stroke Primary Prevention Trial (CSPPT). http://
clinicaltrials.gov/ct2/show/NCT00794885 (accessed July 24, 2010).
